Published in Blood Weekly, August 18th, 2005
As part of the formal completion of the transaction with GSK, Vitae secured $15 million in equity financing from investors, which the company intends to use principally to accelerate its multiple programs into the clinic.
GSK and Vitae formed a strategic alliance in June 2005 to develop and commercialize renin inhibitor drug compounds for the treatment of hypertension and related cardiovascular disorders. As part of this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.